{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:54:37Z","timestamp":1793202877505,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41591-024-03361-4","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:03:39Z","timestamp":1736139819000},"page":"105-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-4531","authenticated-orcid":false,"given":"Andrea M.","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"O\u2019Sullivan Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-6995","authenticated-orcid":false,"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Tibery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1570-3641","authenticated-orcid":false,"given":"William G.","family":"Herrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-657X","authenticated-orcid":false,"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Shern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry V.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5761-9918","authenticated-orcid":false,"given":"Shelley A. H.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Tamula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5926-5084","authenticated-orcid":false,"given":"Olivia","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Sankaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan Prasaad","family":"Govindharajulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-0001","authenticated-orcid":false,"given":"Rosandra N.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heisey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7449-4204","authenticated-orcid":false,"given":"Thomas J.","family":"On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-2024","authenticated-orcid":false,"given":"Xiaoling","family":"Xuei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-5258","authenticated-orcid":false,"given":"Xiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-2248","authenticated-orcid":false,"given":"Barry C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph E.","family":"Parchment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Wade","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-853X","authenticated-orcid":false,"given":"Alice P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-7175","authenticated-orcid":false,"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"3361_CR1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ejca.2010.11.013","volume":"47","author":"A Ferrari","year":"2011","unstructured":"Ferrari, A. et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur. J. Cancer 47, 724\u2013731 (2011).","journal-title":"Eur. J. Cancer"},{"key":"3361_CR2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross, A. M. et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 20, 1643\u20131651 (2018).","journal-title":"Neuro Oncol."},{"key":"3361_CR3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154513","volume":"7","author":"LJ Kershner","year":"2022","unstructured":"Kershner, L. J. et al. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight 7, e154513 (2022).","journal-title":"JCI Insight"},{"key":"3361_CR4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","volume":"159","author":"R Nguyen","year":"2011","unstructured":"Nguyen, R. et al. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J. Pediatr. 159, 652\u2013655 (2011).","journal-title":"J. Pediatr."},{"key":"3361_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","volume":"31","author":"F Canavese","year":"2011","unstructured":"Canavese, F. & Krajbich, J. I. Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J. Pediatr. Orthop. 31, 303\u2013311 (2011).","journal-title":"J. Pediatr. Orthop."},{"key":"3361_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","volume":"89","author":"BR Korf","year":"1999","unstructured":"Korf, B. R. Plexiform neurofibromas. Am. J. Med. Genet. 89, 31\u201337 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"3361_CR7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans, D. G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311\u2013314 (2002).","journal-title":"J. Med. Genet."},{"key":"3361_CR8","first-page":"1573","volume":"62","author":"RE Ferner","year":"2002","unstructured":"Ferner, R. E. & Gutmann, D. H. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 62, 1573\u20131577 (2002).","journal-title":"Cancer Res."},{"key":"3361_CR9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner, R. E. et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44, 81\u201388 (2007).","journal-title":"J. Med. Genet."},{"key":"3361_CR10","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/j.1460-2075.1993.tb05841.x","volume":"12","author":"G Bollag","year":"1993","unstructured":"Bollag, G., McCormick, F. & Clark, R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO J. 12, 1923\u20131927 (1993).","journal-title":"EMBO J."},{"key":"3361_CR11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1523\/JNEUROSCI.3096-13.2014","volume":"34","author":"AF Oliveira","year":"2014","unstructured":"Oliveira, A. F. & Yasuda, R. Neurofibromin is the major ras inactivator in dendritic spines. J. Neurosci. 34, 776\u2013783 (2014).","journal-title":"J. Neurosci."},{"key":"3361_CR12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","volume":"15","author":"LM Messiaen","year":"2000","unstructured":"Messiaen, L. M. et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum. Mutat. 15, 541\u2013555 (2000).","journal-title":"Hum. Mutat."},{"key":"3361_CR13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher, M. J. et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 24, 1827\u20131844 (2022).","journal-title":"Neuro Oncol."},{"key":"3361_CR14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","volume":"22","author":"S Akshintala","year":"2020","unstructured":"Akshintala, S. et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro Oncol. 22, 1368\u20131378 (2020).","journal-title":"Neuro Oncol."},{"key":"3361_CR15","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi, E. et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81, S33\u2013S40 (2013).","journal-title":"Neurology"},{"key":"3361_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-021-00783-z","volume":"23","author":"M Hedayat","year":"2022","unstructured":"Hedayat, M., Jafari, R. & Majidi Zolbanin, N. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. Clin. Exp. Med. 23, 229\u2013244 (2022).","journal-title":"Clin. Exp. Med."},{"key":"3361_CR17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2011-03-340109","volume":"118","author":"S Bhalla","year":"2011","unstructured":"Bhalla, S. et al. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood 118, 1052\u20131061 (2011).","journal-title":"Blood"},{"key":"3361_CR18","volume":"16","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y. et al. Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells. BMC Cancer 16, 818 (2016).","journal-title":"BMC Cancer"},{"key":"3361_CR19","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3361_CR20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3361_CR21","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey, D. et al. FDA approval summary: selumetinib for plexiform neurofibroma. Clin. Cancer Res. 27, 4142\u20134146 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3361_CR22","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.xcrm.2020.100131","volume":"1","author":"WS Brown","year":"2020","unstructured":"Brown, W. S. et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1\/2 complexes in pancreatic cancer. Cell Rep. Med. 1, 100131 (2020).","journal-title":"Cell Rep. Med."},{"key":"3361_CR23","doi-asserted-by":"crossref","first-page":"56698","DOI":"10.18632\/oncotarget.18082","volume":"8","author":"DE Butler","year":"2017","unstructured":"Butler, D. E. et al. Inhibition of the PI3K\/AKT\/mTOR pathway activates autophagy and compensatory Ras\/Raf\/MEK\/ERK signalling in prostate cancer. Oncotarget 8, 56698\u201356713 (2017).","journal-title":"Oncotarget"},{"key":"3361_CR24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","volume":"11","author":"CH Chen","year":"2017","unstructured":"Chen, C. H. et al. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701. Mol. Oncol. 11, 1273\u20131287 (2017).","journal-title":"Mol. Oncol."},{"key":"3361_CR25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.37.4.378","volume":"37","author":"WW Downie","year":"1978","unstructured":"Downie, W. W. et al. Studies with pain rating scales. Ann. Rheum. Dis. 37, 378\u2013381 (1978).","journal-title":"Ann. Rheum. Dis."},{"key":"3361_CR26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/DBP.0000000000000191","volume":"36","author":"L Holmstrom","year":"2015","unstructured":"Holmstrom, L., Kemani, M. K., Kanstrup, M. & Wicksell, R. K. Evaluating the statistical properties of the Pain Interference Index in children and adolescents with chronic pain. J. Dev. Behav. Pediatr. 36, 450\u2013454 (2015).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"3361_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/pme.12620","volume":"16","author":"S Martin","year":"2015","unstructured":"Martin, S. et al. Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report. Pain. Med 16, 367\u2013373 (2015).","journal-title":"Pain. Med"},{"key":"3361_CR28","doi-asserted-by":"crossref","unstructured":"Guy, W. ECDEU Assessment Manual for Psychopharmacology (US Department of Health, Education, and Welfare, 1976).","DOI":"10.1037\/e591322011-001"},{"key":"3361_CR29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1535-7163.MCT-20-0566","volume":"20","author":"WG Herrick","year":"2021","unstructured":"Herrick, W. G. et al. Isoform- and phosphorylation-specific multiplexed quantitative pharmacodynamics of drugs targeting PI3K and MAPK signaling in xenograft models and clinical biopsies. Mol. Cancer Ther. 20, 749\u2013760 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"3361_CR30","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","volume":"13","author":"TC Yeh","year":"2007","unstructured":"Yeh, T. C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor. Clin. Cancer Res. 13, 1576\u20131583 (2007).","journal-title":"Clin. Cancer Res."},{"key":"3361_CR31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-020-00967-y","volume":"60","author":"O Campagne","year":"2021","unstructured":"Campagne, O., Yeo, K. K., Fangusaro, J. & Stewart, C. F. Clinical Pharmacokinetics and pharmacodynamics of selumetinib. Clin. Pharmacokinet. 60, 283\u2013303 (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"3361_CR32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"3361_CR33","first-page":"e661","volume":"100","author":"KI Ly","year":"2023","unstructured":"Ly, K. I. et al. Ten-year follow-up of internal neurofibroma growth behavior in adult patients with neurofibromatosis type 1 using whole-body MRI. Neurology 100, e661\u2013e670 (2023).","journal-title":"Neurology"},{"key":"3361_CR34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss, B. D. et al. NF106: A neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J. Clin. Oncol. 39, 797\u2013806 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3361_CR35","doi-asserted-by":"publisher","unstructured":"Moertel, C. L. et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco.24.01034 (2024).","DOI":"10.1200\/jco.24.01034"},{"key":"3361_CR36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","volume":"27","author":"MJ Fisher","year":"2021","unstructured":"Fisher, M. J. et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat. Med. 27, 165\u2013173 (2021).","journal-title":"Nat. Med."},{"key":"3361_CR37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jaad.2020.07.105","volume":"84","author":"BN Wilson","year":"2021","unstructured":"Wilson, B. N., John, A. M., Handler, M. Z. & Schwartz, R. A. Neurofibromatosis type 1: new developments in genetics and treatment. J. Am. Acad. Dermatol 84, 1667\u20131676 (2021).","journal-title":"J. Am. Acad. Dermatol"},{"key":"3361_CR38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s10637-015-0212-z","volume":"33","author":"K Do","year":"2015","unstructured":"Do, K. et al. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest. New Drugs 33, 720\u2013728 (2015).","journal-title":"Invest. New Drugs"},{"key":"3361_CR39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","volume":"125","author":"CE Prada","year":"2013","unstructured":"Prada, C. E. et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 125, 159\u2013168 (2013).","journal-title":"Acta Neuropathol."},{"key":"3361_CR40","unstructured":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13\u201315, 1987. Neurofibromatosis 1, 172\u2013178 (1988)."},{"key":"3361_CR41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi, E. et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68, 643\u2013647 (2007).","journal-title":"Neurology"},{"key":"3361_CR42","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/01.wnl.0000435748.79908.c5","volume":"81","author":"BC Widemann","year":"2013","unstructured":"Widemann, B. C. et al. Conclusions and future directions for the REiNS International Collaboration. Neurology 81, S41\u2013S44 (2013).","journal-title":"Neurology"},{"key":"3361_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","volume":"67","author":"MM Miettinen","year":"2017","unstructured":"Miettinen, M. M. et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum. Pathol. 67, 1\u201310 (2017).","journal-title":"Hum. Pathol."},{"key":"3361_CR44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin, R. H. et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113, 9\u201319 (2005).","journal-title":"Pain"},{"key":"3361_CR45","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/01.wnl.0000435747.02780.bf","volume":"81","author":"PL Wolters","year":"2013","unstructured":"Wolters, P. L. et al. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology 81, S6\u2013S14 (2013).","journal-title":"Neurology"},{"key":"3361_CR46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307\u2013321 (2012).","journal-title":"Cell"},{"key":"3361_CR47","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).","journal-title":"Science"},{"key":"3361_CR48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","volume":"11","author":"TJ Stuhlmiller","year":"2015","unstructured":"Stuhlmiller, T. J. et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 11, 390\u2013404 (2015).","journal-title":"Cell Rep."},{"key":"3361_CR49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"3361_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt, T. et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514, 247\u2013251 (2014).","journal-title":"Nature"},{"key":"3361_CR51","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03361-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:05:20Z","timestamp":1737482720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3361"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03361-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}